PL2739285T3 - Selektywna inhibicja proteazy MALT1 przez pochodne fenotiazyny - Google Patents

Selektywna inhibicja proteazy MALT1 przez pochodne fenotiazyny

Info

Publication number
PL2739285T3
PL2739285T3 PL12741012T PL12741012T PL2739285T3 PL 2739285 T3 PL2739285 T3 PL 2739285T3 PL 12741012 T PL12741012 T PL 12741012T PL 12741012 T PL12741012 T PL 12741012T PL 2739285 T3 PL2739285 T3 PL 2739285T3
Authority
PL
Poland
Prior art keywords
selective inhibition
phenothiazine derivatives
malt1 protease
malt1
protease
Prior art date
Application number
PL12741012T
Other languages
English (en)
Inventor
Daniel KRAPPMANN
Daniel NAGEL
Dolores Schendel
Stefani SPRANGER
Original Assignee
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) filed Critical Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Publication of PL2739285T3 publication Critical patent/PL2739285T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL12741012T 2011-08-02 2012-08-01 Selektywna inhibicja proteazy MALT1 przez pochodne fenotiazyny PL2739285T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006346 2011-08-02
PCT/EP2012/065072 WO2013017637A1 (en) 2011-08-02 2012-08-01 Selective inhibition of malt1 protease by phenothiazine derivatives
EP12741012.4A EP2739285B9 (en) 2011-08-02 2012-08-01 Selective inhibition of malt1 protease by phenothiazine derivatives

Publications (1)

Publication Number Publication Date
PL2739285T3 true PL2739285T3 (pl) 2019-07-31

Family

ID=46598557

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12741012T PL2739285T3 (pl) 2011-08-02 2012-08-01 Selektywna inhibicja proteazy MALT1 przez pochodne fenotiazyny

Country Status (12)

Country Link
US (1) US9504692B2 (pl)
EP (2) EP3473254B1 (pl)
JP (1) JP6069321B2 (pl)
CN (2) CN109999041A (pl)
AU (1) AU2012292016B2 (pl)
CA (1) CA2843338C (pl)
DK (1) DK2739285T3 (pl)
ES (1) ES2716276T3 (pl)
PL (1) PL2739285T3 (pl)
PT (1) PT2739285T (pl)
TR (1) TR201903280T4 (pl)
WO (1) WO2013017637A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
ES2909438T3 (es) 2013-06-26 2022-05-06 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer
CN103709122B (zh) * 2013-11-29 2016-05-25 四川大学 用于治疗的抗肿瘤和抗真菌化合物
US9198916B1 (en) 2014-05-27 2015-12-01 B&G Partners, Llc Compounds and methods for treating tumors
WO2017057695A1 (ja) * 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
US10103402B2 (en) * 2015-12-01 2018-10-16 University Of Kentucky Research Foundation Liquid phenothiazine catholytes for non-aqueous redox flow batteries
US11130741B2 (en) * 2016-06-23 2021-09-28 Bioimics Ab Anti-infective heterocyclic compounds and uses thereof
CN109476599A (zh) 2016-07-29 2019-03-15 东丽株式会社 胍衍生物和其医药用途
RU2021113671A (ru) 2016-07-29 2021-07-08 Люпин Лимитед Замещенные тиазолопиридиновые соединения в качестве ингибиторов malt1
MX2019001132A (es) * 2016-07-29 2019-12-16 Lupin Ltd Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
JPWO2018159650A1 (ja) * 2017-02-28 2019-12-19 東レ株式会社 グアニジン誘導体及びその医薬用途
JP6958860B2 (ja) 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
IL293143A (en) * 2019-11-22 2022-07-01 Janssen Pharmaceutica Nv Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors
CN113264903A (zh) * 2021-05-27 2021-08-17 郑州大学 一种吩噻嗪类化合物及其制备方法和应用
AU2022405443A1 (en) * 2021-12-10 2024-05-30 Rarefied Biosciences, Inc. Methods for treating diseases using malt1 inhibitors
CN116675682A (zh) * 2023-05-23 2023-09-01 郑州大学 一种吩恶嗪类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774883A (en) * 1954-06-21 1957-05-15 Rhone Poulenc Sa Phenthiazine derivatives
US3156692A (en) * 1958-07-23 1964-11-10 Geigy Chem Corp 5-basically substituted dibenzazepine compounds
DE3484745D1 (de) * 1983-10-05 1991-08-01 Merck Frosst Canada Inc Inhibitoren fuer die leukotrien-biosynthese.
GB9416571D0 (en) * 1994-08-16 1994-10-12 Battelle Memorial Institute Novel alkylamino derivatives as sigma 2 selective ligands
US5679651A (en) * 1995-06-05 1997-10-21 Richardson; Bruce C. Treatment for systemic lupus erythematosus
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
US5674329A (en) 1996-04-26 1997-10-07 General Electric Company Adhesive tape covered laser shock peening
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
AU2003222197A1 (en) * 2002-01-16 2003-09-02 The Regents Of The University Of California Inhibition of rna function
CA2488708A1 (en) * 2002-06-17 2003-12-24 Philadelphia Health And Education Corporation (D/B/A Mcp Hahnemann University) Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
EP1744781B1 (en) * 2004-04-30 2012-07-04 BKG Pharma ApS Treatment of infectious diseases
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
EP1948179A1 (en) * 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
AU2007290386A1 (en) * 2006-09-01 2008-03-06 Immune Control, Inc. Novel compositions and methods for treatment of diseases related to activated lymphocytes
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
JP2011513319A (ja) * 2008-02-29 2011-04-28 イミューン コントロール インコーポレイテッド 活性化リンパ球に関連する疾患の処置のための組成物
ES2909438T3 (es) 2013-06-26 2022-05-06 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer

Also Published As

Publication number Publication date
CN103781481A (zh) 2014-05-07
PT2739285T (pt) 2019-03-26
WO2013017637A1 (en) 2013-02-07
US20140288060A1 (en) 2014-09-25
CA2843338C (en) 2020-08-25
AU2012292016B2 (en) 2017-06-01
EP3473254B1 (en) 2024-01-24
JP2014521678A (ja) 2014-08-28
AU2012292016A1 (en) 2014-02-13
EP2739285B9 (en) 2019-09-04
TR201903280T4 (tr) 2019-04-22
DK2739285T3 (en) 2019-04-15
EP2739285B1 (en) 2018-12-26
EP3473254A1 (en) 2019-04-24
EP2739285A1 (en) 2014-06-11
CA2843338A1 (en) 2013-02-07
US9504692B2 (en) 2016-11-29
CN109999041A (zh) 2019-07-12
ES2716276T3 (es) 2019-06-11
JP6069321B2 (ja) 2017-02-01
CN103781481B (zh) 2018-12-14

Similar Documents

Publication Publication Date Title
PT2739285T (pt) Inibição seletiva da protease malt1 por meio de derivados de fenotiazina
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
IL233081A0 (en) History of Betulin
ZA201306175B (en) Isoxazole derivatives
ZA201401884B (en) New dihydroquinoline-2-one derivatives
HUE047354T2 (hu) Ivacaftor deuterizált származékai
LT2709986T (lt) Ivakaftoro deuterinti dariniai
IL238719A0 (en) Small molecule inhibitors of malt1
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
ZA201307428B (en) Thiazole derivatives
SG11201401937YA (en) New aryl-quinoline derivatives
IL247642A0 (en) History of isoxazole
EP2776393A4 (en) NAMPT INHIBITORS
ZA201403302B (en) Method for inhibition of deubiquitinating acttivity
SG11201400452TA (en) Derivatives of xanthone compounds
IL233001A0 (en) New iso-ergoline histories
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
ZA201306074B (en) Cathepsin c inhibitors
IL233550A0 (en) Stable pharmaceutical formulations of an effective hepatitis c virus inhibitor
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
HUE036665T2 (hu) Dihidro-pirido-oxazin származék szilárd formái